PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
August 26, 2021Nature Communications89 citationsOpen Access

Tumour-targeted interleukin-12 and entinostat combination therapy improves cancer survival by reprogramming the tumour immune cell landscape

KHKristin C. HicksPCPaul L. ChariouYOYohei Ozawa

Key Points

Key points are not available for this paper at this time.

Abstract

T cells and activated neutrophils drive macrophage M1-like polarization, leading to complete tumour eradication in 41.7%-100% of cases. Biomarker signature of favourable overall survival in multiple human tumor types shows close resemblance to the immune pattern generated by Entinostat/NHS-rmIL12 combination therapy. Collectively, these findings provide a rationale for combining NHS-IL12 with Entinostat in the clinical setting.

Ask AI
Helpful
Bookmark
Share
View Full Paper

Cite This Study

Hicks et al. (2021) studied this question.

synapsesocial.com/papers/6a0610aea554d208ba1093d8https://doi.org/10.1038/s41467-021-25393-x
Ask AI
Helpful
Bookmark
Share
View Full Paper